⚙
AI-generated deep summary
by qwen3.7-flash, 2026-10-11
· read from full text
ⓘ
This commentary reviews the association between endometriosis and ovarian cancer risk, noting that while absolute risk remains low, specific subtypes like endometrioid and clear cell carcinomas show moderately elevated incidence in affected patients. The authors highlight that deep infiltrating endometriosis and ovarian endometriomas are linked to a nearly tenfold increase in cancer risk, driven by mechanisms such as chronic inflammation, oxidative stress, and ferroptosis resistance. Significant limitations include the retrospective nature of most epidemiological data and heterogeneity in disease definitions, which challenges generalizability and early detection efforts. This paper is centrally about endometriosis — specifically its role as a risk factor for malignant transformation into ovarian cancer.
Abstract
An estimated 10% of reproductive-aged women are affected by endometriosis, a chronic, estrogen-dependent gynecologic disorder characterized by ectopic endometrial-like implants displaced in nonuterine locations throughout the pelvis. Although this condition is not malignant, it does have cancer-like traits and potential for malignant transformation. Both epidemiological and molecular evidence support this association for ovarian cancer, though the absolute risk of ovarian cancer for patients with endometriosis remains low. A systematic literature review was conducted to assess current medical literature on the oncological risk associated with endometriosis. Databases included PubMed, Scopus, and Web of Science. Inclusion criteria for studies were publication date between January 1, 2000, and October 1, 2025, and pertinent reporting of outcomes. Studies focusing on the epidemiology of ovarian cancer consistently report a moderately elevated risk of the disease in patients with endometriosis, particularly in endometrioid and clear cell subtypes. Most epidemiological studies on this topic have been retrospective case-control or cohort studies, which must be interpreted carefully due to inherent bias in study design. Meta-analyses have shown similar findings. Though prospective data are limited, studies that do exist report similar findings, with the addition of an even greater elevated risk for patients with deep infiltrating endometriosis and ovarian endometriomas. However, there is an overall lack of generalizability in epidemiologic studies due to heterogeneity in the definitions of endometriosis across studies. Recent evidence has shown that certain types of endometriosis, such as deep infiltrating endometriosis or ovarian endometriomas, are associated with a 9.66-fold increase in developing ovarian cancer. More severe forms of endometriosis also tend to be more associated with the endometrioid and clear cell ovarian cancer subtypes, likely due to the mechanisms of chronic inflammation, oxidative stress, and immune dysregulation that accompany the more severe forms. One of the central mechanisms of endometriosis is chronic inflammation, which creates the potential for malignant transformation. Inflammatory mediators initiate a cascade of oxidative stress, genomic instability, and dysregulated cell proliferation that contributes to the development of malignancy. Ferroptosis is a regulated form of cell death driven by iron overload and lipid peroxidation. Studies suggest that ferroptosis resistance in epithelial cells and its activation in stromal cells contribute to malignant transformation in patients with endometriosis. Recent studies show that there is significant overlap in genetic and molecular elements of endometriosis and ovarian cancer. The management of endometriosis requires monitoring, particularly in women who have been diagnosed for long periods of time, those who have atypical endometriosis, or those who have large endometriomas. Universally accepted screening for ovarian cancer is not effective, which presents a challenge for early detection in patients with possible elevated risk. The current methods for diagnosis and evaluation of endometriosis have low sensitivity for ovarian cancer in the early stages, which underscores a need for better biomarkers and tools with greater sensitivity for both endometriosis and ovarian cancer. Significant opportunities remain for targeted therapies, though the translation into clinical practice presents a challenge. Ongoing studies are exploring treatments for ovarian cancers that can also address endometriosis-related malignancy, though each still requires further clinical validation before introducing them to clinical practice. Standardizing guidelines that reflect the known risks of ovarian cancer in women with endometriosis to assist in early detection is recommended. (Summarized from Bogani G, Moore KN, Ray-Coquard I, et al. Endometriosis and ovarian cancer risk. Gynecol Oncol . 2026;209:88-98. doi:10.1016/j.ygyno.2026.05.004).
Full text
4,123 characters
· extracted from
oa-doi-fallback
· click to expand
Comment on “Endometriosis and Ovarian Cancer Risk”
- Linda Van Lea
An estimated 10% of reproductive-aged women are affected by endometriosis, a chronic, estrogen-dependent gynecologic disorder characterized by ectopic endometrial-like implants displaced in nonuterine locations throughout the pelvis. Although this condition is not malignant, it does have cancer-like traits and potential for malignant transformation. Both epidemiological and molecular evidence support this association for ovarian cancer, though the absolute risk of ovarian cancer for patients with endometriosis remains low.
A systematic literature review was conducted to assess current medical literature on the oncological risk associated with endometriosis. Databases included PubMed, Scopus, and Web of Science. Inclusion criteria for studies were publication date between January 1, 2000, and October 1, 2025, and pertinent reporting of outcomes. Studies focusing on the epidemiology of ovarian cancer consistently report a moderately elevated risk of the disease in patients with endometriosis, particularly in endometrioid and clear cell subtypes. Most epidemiological studies on this topic have been retrospective case-control or cohort studies, which must be interpreted carefully due to inherent bias in study design. Meta-analyses have shown similar findings. Though prospective data are limited, studies that do exist report similar findings, with the addition of an even greater elevated risk for patients with deep infiltrating endometriosis and ovarian endometriomas. However, there is an overall lack of generalizability in epidemiologic studies due to heterogeneity in the definitions of endometriosis across studies.
Recent evidence has shown that certain types of endometriosis, such as deep infiltrating endometriosis or ovarian endometriomas, are associated with a 9.66-fold increase in developing ovarian cancer. More severe forms of endometriosis also tend to be more associated with the endometrioid and clear cell ovarian cancer subtypes, likely due to the mechanisms of chronic inflammation, oxidative stress, and immune dysregulation that accompany the more severe forms.
One of the central mechanisms of endometriosis is chronic inflammation, which creates the potential for malignant transformation. Inflammatory mediators initiate a cascade of oxidative stress, genomic instability, and dysregulated cell proliferation that contributes to the development of malignancy. Ferroptosis is a regulated form of cell death driven by iron overload and lipid peroxidation. Studies suggest that ferroptosis resistance in epithelial cells and its activation in stromal cells contribute to malignant transformation in patients with endometriosis. Recent studies show that there is significant overlap in genetic and molecular elements of endometriosis and ovarian cancer.
The management of endometriosis requires monitoring, particularly in women who have been diagnosed for long periods of time, those who have atypical endometriosis, or those who have large endometriomas. Universally accepted screening for ovarian cancer is not effective, which presents a challenge for early detection in patients with possible elevated risk. The current methods for diagnosis and evaluation of endometriosis have low sensitivity for ovarian cancer in the early stages, which underscores a need for better biomarkers and tools with greater sensitivity for both endometriosis and ovarian cancer. Significant opportunities remain for targeted therapies, though the translation into clinical practice presents a challenge. Ongoing studies are exploring treatments for ovarian cancers that can also address endometriosis-related malignancy, though each still requires further clinical validation before introducing them to clinical practice. Standardizing guidelines that reflect the known risks of ovarian cancer in women with endometriosis to assist in early detection is recommended.
(Summarized from Bogani G, Moore KN, Ray-Coquard I, et al. Endometriosis and ovarian cancer risk. Gynecol Oncol. 2026;209:88-98. doi:10.1016/j.ygyno.2026.05.004).
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.